Genzyme Corp

Genzyme — Proxy Contest (June 2010)

15 slides from Genzyme's proxy contest presentation, Jun 1, 2010

  1. Slide 1: June 1, 2010

    June 1, 2010

  2. Slide 2: Important Information

    Important Information On April 26, 2010, Genzyme filed a definitive proxy statement with the SEC in connection with the company’s 2010 annual meeting of shareholders. Genzyme shareholders are strongly advised to read carefully the company’s definitive proxy statement and other proxy materials before

  3. Slide 3: Summary perspectives on Mr. Icahn's presentation

    Summary perspectives on Mr. Icahn’s presentation Ignores long-term track record of delivering shareholder value 20+ year track record of biologic manufacturing excellence, contrasted with isolated manufacturing problems at Allston Approval of more than a dozen products by FDA (Lumizyme recent exampl

  4. Slide 4: Benchmarking analysis

    Benchmarking analysis 2009 was an aberration due to manufacturing challenges related to Allston Mr. Icahn points to expenses being high as a percentage of revenue in 2009, but that metric was driven by the lower revenue resulting from the manufacturing interruption Absent supply interruptions, Genzy

  5. Slide 5: Benchmarking analysis (2006, 2007, 2008): appropriate peer set

    Benchmarking analysis (2006, 2007, 2008) Analyzing appropriate peer set – Peer set identified in Proxy Source: Company filings and Genzyme estimates. Note: Medians exclude Genzyme. Genzyme based on Non-GAAP financials and include an adjustment to R&D for license fees of $490.9 million in 2008. See A

  6. Slide 6: Benchmarking analysis: Total shareholder return analysis

    Benchmarking analysis Total shareholder return analysis Genzyme has outperformed the median of its peer group and relevant indices on the basis of total return to shareholders for 2005 - 2008 and 2010 year-to date Source: Bloomberg as of 28-May-2010, company filings. Reflects total return from 31-De

  7. Slide 7: Mr. Icahn's Board "Operational Leadership"?

    Mr. Icahn’s Board “Operational Leadership”? Share price performance, from date added to Board to present (or date of resignation) Source: CapIQ, Shark Repellent and public sources as of 28-May-2010. Note: Absolute return refers to change in company share price from date upon which Mr. Icahn and / or

  8. Slide 8: Steps have been taken which have potential to deliver outsized value

    Steps have been - and continue to be - taken which have potential to deliver outsized value Promising line-up of new launches and late-stage pipeline Lumizyme approval, with Synvisc-One and Mozobil, will drive near-term growth Alemtuzumab continues to show promise as a treatment for MS Divestitures

  9. Slide 9: Appendix

    Appendix

  10. Slide 10: Proposed transactions will improve pro forma 2009 margins and operating returns

    Proposed transactions will improve pro forma 2009 margins and operating returns Genzyme Standalone Genetic Testing Diagnostics Pharmaceuticals Genzyme PF Revenue (millions) $4,516 $371 $167 $30 $3,948 Gross Margin(1) 70.8% 43.4% 38.6% 21.6% 75.2% SG&A as % of Revenue(1) 29.2% 39.3% 27.6% 24.5% 28.2%

  11. Slide 11: Reconciliation of GAAP to Non-GAAP earnings — 2006

    Reconciliation of GAAP to Non-GAAP earnings — 2006 (1) Represents the adjusted Non-GAAP results of operations and financial position for Genzyme Corporation for the year ended December 31, 2006. All other amounts presented above represent previously reported amounts. We believe that certain Non-GAAP

  12. Slide 12: Reconciliation of GAAP to Non-GAAP earnings — 2007

    (1) Represents the adjusted Non-GAAP results of operations and financial position for Genzyme Corporation for the year ended December 31, 2007. All other amounts presented above represent previously reported amounts. We believe that certain Non-GAAP financial measures, when considered together with

  13. Slide 13: Reconciliation of GAAP to Non-GAAP earnings — 2008

    (1) Represents the adjusted Non-GAAP results of operations and financial position for Genzyme Corporation for the year ended December 31, 2008. All other amounts presented above represent previously reported amounts. We believe that certain Non-GAAP financial measures, when considered together with

  14. Slide 14: Reconciliation of GAAP to Non-GAAP Earnings, Year Ended December 31, 2009

    GENZYME CORPORATION RECONCILIATION OF GAAP TO NON-GAAP EARNINGS For the Year Ended December 31, 2009 (Amounts in thousands, except percentage and per share data) GAAP As Reported Bayer Acquisition Related (2) FAS 123R Expense NON-GAAP (1) Income Statement Classification: Total revenues Cost of produ

  15. Slide 15: Positioned for Success in 2010-2014

    Positioned for Success in 2010-2014 Horizon Maximize the brand opportunity Protect and extend market timeline Retain value post- patent expiry First 12 years 12 $4.0B Next 5 years 5 $4.2B Revenue 5 Source: Genzyme long range estimates

Genzyme — Proxy Contest (June 2010) on 6ix